Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease

Journal of Pharmacological Sciences

Volumn 100, Issue 1, 2006, Pages 59-64

  Nakatsuka, Akiko ^a   Nagai, Masahiro ^a   Yabe, Hayato ^a   Nishikawa, Noriko ^a   Nomura, Takuo ^a   Moritoyo, Hiroyoko ^a   Moritoyo, Takashi ^b   Nomoto, Masahiro ^a,b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cabergoline; Clarithromycin; Drug drug interaction; Parkinson's disease

Indexed keywords

BENSERAZIDE; CABERGOLINE; CARBIDOPA; CLARITHROMYCIN; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEARTBURN; HUMAN; MALE; NAUSEA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT DURATION;

EID: 31544455549     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0050711     Document Type: Article

References (27)

1. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20:523-539.
2. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology.1998;50 (3 Suppl3):S1-S57.
3. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs.1998;55 Suppl 1:23-30.
4. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41:261-309.
5. Nomoto M, Kita S, Iwata SI, Kaseda S, Fukuda T. Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets. Pharmacol Biochem Behav.1998;59:717-721.
6. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol. 1996;243:68-72.
7. Battaglia R, Strolin Benedetti M, Mantegani S, Castelli MG, Cocchiara G, Dostert P. Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica. 1993;23:1377-1389.
8. Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42:633-645.
9. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999;37:385-398.
10. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos. 1997;25:623-630.
11. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50:285-295.
12. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In : Fahn S, Goldstein M, Marsden D, Calne DB, editors. Recent developments in Parkinson's disease. Volume II. New Jersey: Macmillan; 1987. p. 153-163.
13. Stebbins GT, Goetz CG. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section. Mov Disord. 1998;13:633-636.
14. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord. 2002;17:867-876.
15. Allievi C, Dostert P. Quantitative determination of cabergoline in human plasma using liquid chromatography combined with tandem mass spectrometry. Rapid Commun Mass Spectrom. 1998;12:33-39.
16. Persiani S, Rocchetti M, Pacciarini MA, Holt B, Toon S, Strolin-Benedetti M. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. Biopharm Drug Dispos. 1996;17:443-455.
17. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64:123-128.
18. Del Dotto P, Colzi A, Musatti E, Strolin Benedetti M, Persiani S, Fariello R, et al. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. Clin Neuropharmacol. 1997;20:455-465.
19. Del Dotto P, Colzi A, Pardini C, Lucetti C, Dubini A, Grimaldi R, et al. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients. J Neural Transm Suppl. 1995;45:259-265.
20. Dostert P, Strolin Benedetti M, Persiani S, La Croix R, Bosc M, Fiorentini F, et al. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. J Neural Transm Suppl. 1995;45:247-257.
21. Ausband SC, Goodman PE. An unusual case of clarithromycin associated ergotism. J Emerg Med. 2001;21:411-413.
22. Christensen J, Dupont E, Ostergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. Mov Disord. 2002;17:1360-1362.
23. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol. 2001;88:187-191.
24. Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004;44:919-927.
25. Ohmoto T, Kishikawa H. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism. Folia Psychiatr Neurol Jpn. 1975;29:1-12.
26. Myllyla VV, Sotaniemi KA, Illi A, Suominen K, Keranen T. Effect of entecapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol. 1993;45:419-423.
27. Kaseda S, Nomoto M, Iwata S. Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res. 1999;815:44-50.